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Synergistic effects of proteasome inhibitor carfilzomib in
combination with tyrosine kinase inhibitors in imatinib-sensitive
and -resistant chronic myeloid leukemia models
LJ Crawford1, ET Chan2, M Aujay2, TL Holyoake3, JV Melo4,5, HG Jorgensen3, S Suresh1, B Walker6 and AE Irvine1
The tyrosine kinase inhibitor (TKI) imatinib has transformed the treatment and outlook of chronic myeloid leukemia (CML); however,
the development of drug resistance and the persistence of TKI-resistant stem cells remain obstacles to eradicating the disease.
Inhibition of proteasome activity with bortezomib has been shown to effectively induce apoptosis in TKI-resistant cells. In this study,
we show that exposure to the next generation proteasome inhibitor carfilzomib is associated with a decrease in ERK signaling and
increased expression of Abelson interactor proteins 1 and 2 (ABI-1/2). We also investigate the effect of carfilzomib in models of
imatinib-sensitive and -resistant CML and demonstrate a potent reduction in proliferation and induction of apoptosis in a variety of
models of imatinib-resistant CML, including primitive CML stem cells. Carfilzomib acts synergistically with the TKIs imatinib and
nilotinib, even in imatinib-resistant cell lines. In addition, we found that the presence of immunoproteasome subunits is associated
with an increased sensitivity to carfilzomib. The present findings provide a rational basis to examine the potential of carfilzomib in
combination with TKIs as a potential therapy for CML, particularly in imatinib-resistant disease.
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INTRODUCTION
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm
that arises in a hematopoietic stem cell. It is characterized by a
reciprocal translocation between the long arms of chromosomes 9
and 22. The resulting fusion gene BCR-ABL, encodes a constitu-
tively active protein tyrosine kinase Bcr-Abl, which is responsible
for the pathogenesis of CML. Current first-line therapy for CML is
imatinib mesylate (imatinib, Glivec; Novartis Pharmaceuticals), a
small molecule tyrosine kinase inhibitor (TKI) specifically designed
to inhibit the Bcr-Abl tyrosine kinase. Imatinib has dramatically
improved the treatment of CML, inducing durable responses in
the majority of patients with chronic phase CML. Nevertheless,
two key issues remain—a number of patients develop resistance1
and primitive CML stem cells are insensitive to imatinib.2 The most
common mechanisms of resistance are mutations in the kinase
domain that affect imatinib binding,3 BCR-ABL amplification4 and
altered drug efflux or influx.5 Second and third generation TKIs
such as dasatinib, nilotinib6 and ponatinib7 demonstrate clinical
efficacy in some cases of imatinib resistance; however, CML stem
cells remain insensitive.8,9 This highlights the need to find
alternative therapeutic strategies to overcome resistance and
eliminate the CML stem cell.
The proteasome is an enzymatic complex that has a key role in
regulating cellular processes through selective degradation of
intracellular proteins. There are three distinct enzymatic activities
associated with the proteasome—chymotrypsin-like (CT-L),
trypsin-like (T-L) and caspase-like (C-L)—mediated by subunits
b5, b2 and b1, respectively. Upon exposure to interferon (IFN)-g
and tumor necrosis factor-a, an alternative form of the protea-
some is formed, referred to as the immunoproteasome. The
immunoproteasome expresses subunits LMP7, MECL1 and LMP2
in place of b5, b2 and b1, altering the proteasome to favor the
generation of antigenic peptides.10 Over the last decade, the
proteasome has emerged as a therapeutic target in hematopoietic
malignancies. Bortezomib, the first-in-class proteasome inhibitor
(PI) validated the proteasome as a therapeutic target and has
provided significant advancement in the treatment of multiple
myeloma (MM)11 and mantle cell lymphoma.12 Clinical benefit has
also been seen with bortezomib-based combinations for non-
Hodgkin’s lymphoma,13 myelodysplastic syndromes14 and acute
myeloid leukemia.15 Following bortezomib’s success, there are a
number of next generation PIs with improved pharmacological
properties in clinical trials. The next generation compound
carfilzomib is an epoxyketone-based inhibitor that binds
irreversibly to the proteasome. Carfilzomib has recently been
approved by the FDA for the treatment of relapsed/refractory MM
and demonstrates greater efficacy and fewer side effects than
bortezomib.16,17
A number of studies support a potential role for the use of PIs in
CML. In vitro studies demonstrated that bortezomib alone and in
combination with kinase inhibitors is effective in imatinib-resistant
CML cells.18–20 In addition, we have previously shown that BCR-ABL
activity is associated with increased proteasome activity, and
that CML cell lines are more susceptible to PIs than normal
counterparts.21 In this study, we evaluate the activity of
carfilzomib alone and in combination with TKIs imatinib and
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nilotinib, using imatinib-sensitive and -resistant CML models. We
demonstrate a downregulation of phosphorylated ERK and
accumulation of Abelson interactor proteins 1 and 2 (ABI 1/2),
along with induction of apoptosis and inhibition of proliferation
by carfilzomib in imatinib-sensitive and -resistant cell lines and
CD34þ38 -enriched CML stem cells. We show that the
combination of carfilzomib with imatinib or nilotinib results in
synergistic effects, even in imatinib-resistant cell lines. Finally, we
demonstrate that the immunoproteasome is a major constituent
of the total proteasome in the majority of CML cell lines and
primary CML cells and that the presence of immunoproteasome
subunits is associated with an increased sensitivity to carfilzomib.
RESULTS
Effect of carfilzomib on key signaling pathways in CML
Cell lines and primary cells were pulsed with carfilzomib at IC50
doses for 1 h and returned to fresh medium for 24 h before protein
lysates were prepared and immunoblot analysis was performed to
determine the effect of carfilzomib on Bcr-Abl signaling pathways.
Carfilzomib treatment resulted in a decrease of p-ERK by 52±11%
(Po0.01), with no effect on STAT5 or PI3K signaling pathways
(Figure 1a). We next looked at the effect of carfilzomib treatment
on ABI 1/2 proteins, which have been reported to inhibit ERK
activation that was induced by v-Abl.22 ABI 1/2 proteins have been
shown to be stable in normal cells but rapidly degraded via the
ubiquitin–proteasome pathway in Bcr-Abl expressing cells.23 We
observed increased expression of ABI 1/2 in cells in which BCR-ABL
was knocked down using siRNA and also in NBM CD34þ38 -
enriched cells compared with CML counterparts (Supplementary
Figure 1). Treatment with carfilzomib at IC50 levels increased the
expression of ABI 1/2 in cell lines and primary CD34þ38 -
enriched cells (range 2.2–6.8 fold, Figure 1b) and this was
associated with an accumulation of polyubiquitinated ABI 1/2
(Figure 1c). ABI 2 has been reported to be tagged for degradation
by the E3 ligase TRIM32 in head and neck cancer.24 Figure 1d
demonstrates an association of ABI 2 with TRIM32 in the CML cell
lines, which appears to be enhanced following treatment with
carfilzomib, suggesting that TRIM32 also acts as an E3 ligase to
target ABI proteins for degradation in Bcr-Abl expressing cells.
Antiproliferative and apoptotic effects of carfilzomib in models of
imatinib-sensitive and -resistant CML
CML cell lines were treated either continuously or pulsed for 1 h
with increasing concentrations of carfilzomib (1–1000 nM) for up to
72 h. A time- and dose-dependent decrease in viability was
observed in all cell lines with an IC50 of o15 nM at 24 h cultured
continuously in the presence of carfilzomib (Figure 2a). To mimic
the in vivo pharmacokinetics of carfilzomib, cell lines were pulsed
for 1 h with the same concentrations of carfilzomib, followed by
growth in drug-free medium for up to 72 h. This treatment also
induced a time- and dose-dependent decrease in viability,
although higher concentrations were required to achieve IC50
(20–79 nM, 24 h) (Figure 2b). Under both conditions, imatinib-
resistant cell lines displayed equal or greater sensitivity to
carfilzomib as their imatinib-sensitive counterparts.
CD34þ38 cells were enriched from three CML patient
samples and normal bone marrow (NBM). As numbers of this
enriched cell population are small, cells were exposed to a median
dose of 50 nM carfilzomib for 1 h before being transferred to drug-
free medium. After 24 h, the viability of CML CD34þ38 cells was
reduced by 39±1 % compared with 19±2 % in NBM (P¼ 0.02;
Figure 2c). To assess the effect of carfilzomib on longer-term stem
cell proliferation, CD34þ cells were enriched from CML (n¼ 3) and
NBM samples (n¼ 2), pulsed for 1 h with 50 nM carfilzomib and
transferred to LTC-IC assays. Colony formation was reduced by
58±11% in CML stem cells compared with 44±7% in normal
stem cells (P¼ 0.04; Figure 2d).
The effect of 1-h exposure to carfilzomib on the induction of
apoptosis in CML cell lines and primary samples was investigated.
Pulse treatment with carfilzomib at IC50 doses induced an increase
in caspase-3 activity along with an associated increase in the
number of sub G0/G1 events, indicative of apoptosis
(Supplementary Figure 2). Further analysis demonstrated induc-
tion of apoptosis through both the caspase-8 and -9 pathways,
consistent with previous reports (Figure 2e).25
Synergistic activity of carfilzomib with TKIs imatinib and nilotinib
The combination of carfilzomib and imatinib or nilotinib was
assessed in imatinib-sensitive and -resistant cell lines. Combina-
tions were set up with all drugs using IC12.5, IC25, IC50 and IC75
values for imatinib-sensitive cell lines and drugs were combined in
three ways: (i) carfilzomib and imatinib/nilotinib were added to
cells simultaneously; (ii) cells were treated with carfilzomib at
t¼ 0 h, followed by imatinib/nilotinib at t¼ 24 h; (iii) cells were
treated with imatinib/nilotinib at t¼ 0 h, followed by carfilzomib at
t¼ 24 h. Proliferation was assessed 48 h after first drug treatment.
Calcusyn software was used to calculate a combination index (CI),
whereby a value less than, equal to or greater than 1 indicates
synergy, additivity or antagonism, respectively.
In imatinib-sensitive cell lines, all combinations of carfilzomib
with the TKIs significantly reduced cell viability and proliferation
compared with either drug alone (Po0.05) and were found to be
synergistic (CI 0.241–0.941; IC50 values). There was no significant
difference dependent on the order in which the drugs were added
or the TKI used. To assess synergy in imatinib-resistant cell lines,
IC50 values derived for the TKIs in imatinib-sensitive cell lines were
used. Both, the simultaneous combination of carfilzomib and a TKI
and the addition of either TKI before carfilzomib resulted in
antagonistic effects (CI 1.053–4.553; IC50). Pretreatment with
carfilzomib for 24 h followed by addition of a TKI resulted in a
significant reduction in viability and proliferation compared with
carfilzomib alone in 4 out of 5 imatinib-resistant cell lines (Pp0.04;
P¼ 0.06 for Ba/F3 H396P cells) and synergy in all imatinib-resistant
cell lines (CI 0.609–0.895; IC50). Using p-CRKL as a marker of Bcr-Abl
kinase activity, we show that the sequential combination of
carfilzomib and a TKI had no effect on p-CRKL, therefore
demonstrating that the synergy observed is independent of Bcr-
Abl inhibition (Figure 3c). Cell viability following combinations of
carfilzomib and imatinib is represented graphically in Figures 3a
and b, and CI values and cell proliferation for all combinations
using IC50 values are given in Supplementary Table 1 and
Supplementary Figure 3.
We next investigated if the combination of carfilzomib and a TKI
demonstrated a beneficial effect in CML cells. CD34þ cells were
enriched from primary CML samples (n¼ 3) and treated as follows:
50 nM carfilzomib, 1 mM imatinib or 30 nM nilotinib used as single
agents, or carfilzomib combined simultaneously and sequentially
at the prior indicated concentrations. Cells treated with single
agent or combined simultaneously were exposed to inhibitors for
24 h; for sequential treatment the cells were exposed to
carfilzomib for 24 h followed by either TKI for 24 h. LTC-IC assays
were then performed on all cell treatments. No further decrease in
colony formation was observed when carfilzomib was combined
simultaneously with either TKI, compared with carfilzomib as a
single agent. A reduction in colony formation from 42% with
carfilzomib treatment alone, to 35%, and 40% of control following
sequential treatment with imatinib and nilotinib was observed
(Figure 3d); however, the difference was not significant (P¼ 0.06
and P¼ 0.19, respectively).
Proteasome profiles and subunit selectivity of carfilzomib in CML
Carfilzomib has been demonstrated to primarily target CT-L
subunits of both the constitutive proteasome (b5) and immuno-
proteasome (LMP7) in MM and lymphoma cells.26,27 To evaluate
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the inhibitory effect of carfilzomib in CML cells, we quantified the
levels of constitutive proteasome and immunoproteasome
subunits in primary CML cells, normal mononuclear cells and
imatinib-sensitive and -resistant CML cell lines (Supplementary
Table 2). In primary cells, the amount of active proteasome
subunits per total protein concentration was significantly higher in
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Figure 1. Mechanisms of action associated with carfilzomib in CML. (a, b) Cells were exposed to IC50 values of carfilzomib for 1 h, followed by
growth in drug-free medium for 24 h before being harvested and whole cell lysates prepared. (a) Western blot analysis for activated
(phosphorylated) ERK, Stat5 and PI3K signaling pathways following exposure to carfilzomib, total levels of ERK, Stat5 and PI3K were used as a
loading control. Densitometry analysis is expressed as a percentage of untreated control, corrected to loading controls and the average results
across cell lines and primary cells are given. Phosphorylated ERK was significantly decreased following carfilzomib treatment (Po0.01).
(b) Western blot analysis of ABI 1/2 levels with and without exposure to carfilzomib. Densitometry analysis is expressed as a percentage
of untreated control, corrected to loading controls and the average results across cell lines and primary cells are given.
(c) Co-immunoprecipitation of ubiquitin and ABI 1/2 in CML cell lines with and without exposure to carfilzomib. Densitometry analysis is
expressed as fold change from untreated control, corrected to input control. (d) Co-immunoprecipitation of TRIM32 and ABI-2 in CML cell lines
with and without exposure to carfilzomib. Densitometry analysis is expressed as fold change from untreated control, corrected to input
control.
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CML cells compared with normal donors (24.05±1.38 ng/mg
vs 16.69±2.86 ng/mg, P¼ 0.001), consistent with our previous
observations that Bcr-Abl activity is associated with increased
proteasome activity.21 We found that immunoproteasome sub-
units were the major constituent of total proteasome in primary
cells (59.1–65.4%) and Ba/F3 cell lines (61.1–70.2%), and com-
prised 16.3–30.1% of total proteasome in KCL22-S and -R and
LAMA84-S and -R CML cell lines (Table 1). This is in agreement
with previous reports on cells of hematopoietic origin27,28 and
confirms that the immunoproteasome is a substantive component
of total proteasome in myeloid as well as lymphoid cells. The
amount of CT-L subunits relative to total cellular protein was
similar across all cell lines and primary CML cells (6.29±1.04ng/mg).
LMP7 was the predominant form of CT-L subunit expressed in
normal mononuclear cells (83.8%), CML mononuclear cells (76.6%)
and Ba/F3 cell lines (52.6–65.8%), and accounted for a significant
proportion of CT-L activity in human CML cell lines (36.6–51.2%)
(Figure 4a). In keeping with previous observations, we found that
primary CML cells and KCL22-S and -R and LAMA84-S and -R
predominantly express the immunoproteasome subunit LMP7
(12–25.3%) relative to MECL1 (2.2–15.2%) and LMP2 (1.2–18.6%).26
The contribution of individual proteasome subunits in Ba/F3 cell
lines differs quite markedly from both primary cells and human
CML cell lines. We have previously demonstrated that the
proteasome subunit profiles are cell type dependent29 and this
difference may reflect the different lineage origin and species of
the cell lines.
To examine the effect of carfilzomib on individual proteasome
activities, cell lines were pulsed with increasing concentrations of
carfilzomib (1–1000 nM) for 1 h and analyzed using the ProCISE
assay. Whereas there was a dose-dependent inhibition of all
proteasome activities (Figures 4b–d), carfilzomib displayed pre-
ferential inhibitory activity against CT-L subunits, with IC50 values
of p8.32 nM for the b5 subunit and p16.55 nM for LMP7. IC50
values for T-L and C-L subunits were at least threefold higher
(Supplementary Table 3).
Pe
rc
en
ta
ge
 o
f C
on
tro
l
Carfilzomib (Log M)
Pe
rc
en
ta
ge
 o
f C
on
tro
l
Carfilzomib (Log M)
0
20
40
60
80
100
120
Normal CD34+
CD38-
CML CD34+
CD38-
Control
+ carfilzomib
p = 0.02
0
20
40
60
80
100
120
Normal CML
Control
+ carfilzomib
p = 0.04
Carfilzomib -   - -
GAPDH 
 
Caspase-9
Caspase-8
LAMA84S KCL22S Ba/F3
p210
CML
CD34+38-
Ba/F3
T351I 
LAMA84R KCL22R
0 1 2 3 4
0
50
100
Ba/F3 p210
Ba/F3 T315I
Ba/F3 H396P
Ba/F3 M351T
0 1 2 3 4
0
50
100 KCL22S
KCL22R
0 1 2 3 4
0
50
100 KCL22S
KCL22R
0 1 2 3 4
0
50
100 LAMA84S
LAMA84R
0 1 2 3 4
0
50
100 LAMA84S
LAMA84R
0 1 2 3 4
0
50
100
Baf3 p210
Baf3 T315I
Baf3 M351T
Baf3 H396P
+ + + - + - +- + - +
Figure 2. Effects of carfilzomib on cell viability in models of imatinib-sensitive and -resistant CML. (a) Viability of CML cell lines following 24 h
culture with increasing doses of carfilzomib (1–1000 nM). (b) Viability of CML cell lines following 1h exposure to increasing doses of carfilzomib
(1–1000 nM); cells were pulsed with carfilzomib followed by culture in drug-free medium for 24 h. Cell lines are grouped as parental imatinib-
sensitive cell lines alongside their imatinib-resistant counterparts. (c) Viability of CML CD34þ38 cells and normal CD34þ38 cells exposed
to 50 nM carfilzomib for 1 h followed by 24 h growth in drug-free medium. Viability of CML CD34þ38 was significantly reduced compared
with NBM (P¼ 0.02). (a–c) All results are expressed as percentage of untreated control and represent mean±s.d. (n¼ 3). (d) CML (n¼ 3) and
normal (n¼ 2) CD34þ cells were exposed to 50 nM carfilzomib followed by long-term culture in LTC-IC assays. Results are expressed as
percentage of control colony count and represent mean±s.d. There was significantly less colony growth in CML LTC-IC compared with NBM
(P¼ 0.04). (e) Western blot analysis for activated (cleaved) caspase-8 and caspase-9 following exposure to carfilzomib.
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The presence of immunoproteasome subunits increases sensitivity
to carfilzomib
We, along with others, have reported that the sensitivity of tumor
cells to PIs may be associated with differential expression of
proteasome subunits.28–30 In this study, we found that in contrast
to the proteasome profiles observed for CML cell lines and primary
samples above, immunoproteasome subunits made little or no
contribution to the overall proteasome activity in K562 cells
(Supplementary Table 2). In this regard, the K562 cell line is more
similar to a nonhematopoietic cell line. We demonstrate that
although carfilzomib is a potent inhibitor of the b5 CT-L subunit in
K562 cells (IC50¼ 6.68 nM; Supplementary Table 2), the IC50 value
for carfilzomib in reducing the proliferation of this cell line was
4fivefold higher than the corresponding values for the other CML
cell lines. We therefore sought to investigate whether the
difference in sensitivity we observed with K562 cells was related
to immunoproteasome expression. A549 lung carcinoma cell line,
known to express low amounts of immunoproteasome,26 was
included as a comparison. K562 and A549 cells were cultured
in the presence of 100U/ml IFN-g for 72 h to induce
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Figure 3. Carfilzomib and TKIs act synergistically in CML cell lines. (a) Viability of imatinib-sensitive cell lines following 48 h culture with
carfilzomib, imatinib or a combination of both at IC12.5, IC25, IC50 or IC75 doses. Using IC50 values all combinations were significantly reduced
compared to either drug alone (Po0.05). (b) Proliferation of imatinib-resistant cell lines following 48 h culture with carfilzomib, imatinib or a
combination of both at IC12.5, IC25, IC50 or IC75 doses. For imatinib-resistant cell lines the IC values used for imatinib were the same as that used
for imatinib-sensitive cell lines. Drugs were combined in three ways—(i) both drugs were added to cells simultaneously, (ii) cells were treated
with carfilzomib first at t¼ 0, followed by imatinib at t¼ 24, or (iii) cells were treated with imatinib first at t¼ 0, followed by carfilzomib at
t¼ 24. Results are expressed as a percentage of untreated control and represent mean±s.d. (n¼ 3). Pretreatment with carfilzomib followed by
addition of imatinib resulted in a significant reduction in viability in Ba/F3 T315I, Ba/F3 M351T, LAMA84R and KCL22R (Pp0.04). (c) Western
blot analysis of phosphorylated-CRKL in imatinib-sensitive and -resistant cell lines following exposure to carfilzomib, imatinib or a
combination of carfilzomib at t¼ 0, followed by imatinib at t¼ 24; whole cell lysates were prepared 48 h after exposure to the first drug.
(d) CML CD34þ cells (n¼ 3) were cultured in the presence of carfilzomib, imatinib, nilotinib or a combination of carfilzomib plus imatinib/
nilotinib either simultaneously or carfilzomib at t¼ 0, followed by imatinib/nilotinib at t¼ 24; after 48 h, cells were transferred to LTC-IC assays.
Results are expressed as percentage of control colony count and represent mean±s.d.
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immunoproteasome expression, before treatment with carfilzomib
(1–1000 nM continuous exposure for 24 h). IFN-g treatment
resulted in an increase in the expression of LMP7 by fourfold
in K562 cells and 10-fold in A549 cells (Figures 5a and b);
IFN-a treatment produced similar results (Supplementary
Figure 4C). The increase in LMP7 expression corresponded with
Table 1. Percentage of constitutive (c20S) and immunoproteasome (i20S) subunits contributing to CT-L, T-L and C-L and total proteasome activity in
CML cell lines and primary cells
CT-L T-L C-L Total
b5 LMP7 S.D. b2 MECL1 S.D. b1 LMP2 S.D. c20S i20S
CML 23.4 76.6 0.7 52.9 47.1 2.2 46.4 53.6 3.3 40.9 59.1
NBM 16.2 83.8 3.8 49.6 50.4 5.7 38.1 61.9 4.9 34.6 65.4
KCL22S 51.3 48.7 2.4 89.3 10.7 2.2 71.1 28.9 1.8 69.9 30.1
KCL22R 59.4 40.6 2.6 93.5 6.5 1.9 88.5 11.5 11.9 81.1 18.9
LAMA84S 48.8 51.2 8.8 89.5 10.5 1.3 94.9 5.1 1.5 75.4 23.9
LAMA8R 63.4 36.6 2.9 91.9 8.1 2.3 96.4 3.6 5.2 83.7 16.3
Ba/F3 p210 34.2 65.8 7.6 84.9 15.1 2.9 1.9 98.1 ND 35.8 64.2
Ba/F3 T315I 47.4 52.6 13.7 90.2 9.8 4.2 7.6 92.4 0.4 38.9 61.1
Ba/F3 M351T 43.9 56.1 11.1 91.1 8.9 6.3 1.7 98.3 1.1 31.9 68.1
Ba/F3 H396P 39.2 60.8 10.6 91.2 8.8 2.1 3.4 96.6 ND 29.8 70.2
K562 97.3 2.7 1.03 97.5 97.5 0.4 93.6 6.4 4.9 95.9 4.1
Abbreviation: ND, not detected.
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a significantly increased sensitivity to carfilzomib (IC50 value
reduced from 608 nM to 179 nM in K562 cells and 92 nM to 10 nM in
A549 cells, Pp0.01; Figures 5c and d). Conversely, we looked at
the effect of LMP7 knockdown on the sensitivity of cells to
carfilzomib. KCL22S and LAMA84S cells were treated with siRNA
targeted against LMP7 before treatment with carfilzomib
(1–1000 nM continuous exposure for 24 h). Downregulation of
LMP7 (Supplementary Figure 4) was associated with a significant
decrease in sensitivity to carfilzomib; the IC50 value for KCL22S
cells increased from 5nM to 16 nM (P¼ 0.01) and LAMA84S cells
increased from 7nM to 20 nM (P¼ 0.04). These results demonstrate
that the presence of both the b5 and LMP7 CT-L subunits are
required for optimal effect with carfilzomib and pretreatment with
IFN-g can sensitize cells to carfilzomib.
DISCUSSION
Although the introduction of TKIs into the clinic has provided a
major advancement in the treatment of CML, the development of
drug resistance and persistence of TKI-resistant stem cells remain
obstacles to eradicating the disease. The proteasome has become
a validated target for cancer therapy, particularly in hematological
malignancies. A number of reports demonstrate that bortezomib
induces apoptosis in BCR-ABL expressing cells, including those
resistant to imatinib and suggest that PIs may have significant
activity in CML.18–20,31 To date, only one study has investigated
the clinical activity of bortezomib in CML. The pilot study
demonstrated minimal efficacy of bortezomib as a single agent
in imatinib-refractory CML and suggested that future trials should
focus on alternative use of PIs in CML, such as combination-based
treatments.32 In support of this, a recent report by Dewer et al.,31
demonstrates that a bortezomib-based regimen resulted in a
complete hematological, cytogenetic and molecular remission in
BCR-ABLþ acute lymphoblastic leukemia. Until recently, bortezo-
mib was the only PI licensed for use in the clinic and its use can be
restricted by limiting side effects such as peripheral neuropathy.17
However, the next generation PI carfilzomib has received FDA
approval for the treatment of relapsed/refractory myeloma and
appears to exhibit less toxicities than bortezomib. In this study, we
have analyzed the effect of carfilzomib, both on its own and in
combination with TKIs, in cell lines that reflect a wide spectrum
of imatinib resistance and in CD34þ38 populations, which
represent the TKI-resistant stem cell population.
Bcr-Abl activates multiple downstream signaling pathways,
including ERK, PI3K and STAT5 pathways, which contribute to
leukemic cell proliferation and survival. We analyzed the effect of
carfilzomib on these signaling pathways and found that exposure
to carfilzomib resulted in a downregulation of phosphorylated
ERK; this effect was replicated across all cell line models and
primary CD34þ38 cells. A previous study by Orlowski et al.,33
has also suggested inhibition of ERK signaling as a key factor in
proteasome inhibitor-mediated apoptosis. Following on from this,
we investigated the effect of carfilzomib on ABI proteins that have
been reported to negatively regulate cell growth and transforma-
tion by specifically targeting the ERK pathway.22 ABI proteins were
originally identified as binding partners of the Abl tyrosine kinase
and two highly homologous members of this family, ABI-1 and
ABI-2, were shown to be rapidly degraded through the ubiquitin–
proteasome system in Bcr-Abl-expressing cells.23 In keeping with
the findings by Dai et al.,23 we found that ABI 1/2 levels were
higher in normal compared with CML CD34þ38 cells and also
that ABI 1/2 expression increased in CML cell lines in which
BCR-ABL was knocked down. Treatment with carfilzomib resulted
in a similar increase in ABI 1/2 protein expression by preventing
the degradation of these proteins through the proteasome, as
proved by the accumulation of polyubiquitinated ABI 1/2. ABI-2 in
particular, has been documented to act as a tumor suppressor and
an inhibitor of cell migration.24,34,35 Kano et al.,24 demonstrated
that the E3 ligase TRIM32 is responsible for mediating the
degradation of ABI-2 in head and neck squamous cell carcinoma,
thereby promoting tumor cell growth, metastasis and drug
resistance.34 In this study, we have demonstrated a protein–
protein interaction between ABI-2 and TRIM32 and observed an
accumulation of this protein interaction following treatment with
carfilzomib, suggesting that TRIM32 may also act as an E3 ligase
for ABI-2 in Bcr-Abl expressing cells. The role of Bcr-Abl in
12
10
8
6
4
2
0
12
10
8
6
4
2
0
n
g/
ug
 To
ta
l P
ro
te
in
n
g/
ug
 To
ta
l P
ro
te
in
K562
K562
Control
+ IFN gamma
+ IFN gamma + IFN gamma
Control
+ IFN gamma
Be
ta5
LM
P7
Be
ta2
Me
cl1
Be
ta1
LM
P2
Proteasome Subunit
Be
ta5
LM
P7
Be
ta2
ME
CL
1
Be
ta1
LM
P2
Proteasome Subunit
A549
A549120
90
60
30
0
0 10 100 1000
Carfilzomib (nM)
0 10 100 1000
Carfilzomib (nM)
0 10 100 1000
Carfilzomib (nM)
0 10 100 1000
Carfilzomib (nM)
%
 o
f C
on
tro
l
%
 o
f C
on
tro
l
%
 o
f C
on
tro
l
120
90
60
30
0
%
 o
f C
on
tro
l
100
80
60
40
20
0
100
80
60
40
20
0
KCL22S
Control
Scrambled
siRNA
Control
Scrambled
siRNA
LAMA84S
a b
c d
e f
Figure 5. The presence of immunoproteasome subunits increases
sensitivity to carfilzomib. (a) Levels of proteasome active site
subunits in K562 cells before and after exposure to 100U/ml IFN-g
(n¼ 3). (b) Levels of proteasome active site subunits in A549 cells
before and after exposure to 100U/ml IFN-g (n¼ 3). (c) Proliferation
of control K562 cells and K562 cells cultured in the presence of
IFN-g, following 1 h exposure to increasing doses of carfilzomib
(1–1000 nM). Results are expressed as a percentage of untreated
control cells and represent mean±s.d. (n¼ 3). (d) Proliferation of
control A549 cells and A549 cells cultured in the presence of IFN-g,
following 1 h exposure to increasing doses of carfilzomib
(1–1000 nM). Results are expressed as a percentage of untreated
control cells and represent mean±s.d. (n¼ 3). (c, d) Exposure to INF-
g significantly increased sensitivity to carfilzomib (Po0.01).
(e) Proliferation of control KCL22S cells and KCL22S cells transfected
with either scrambled siRNA or siRNA targeted against LMP7
following 24 h exposure to increasing doses of carfilzomib
(1–1000 nM). Results are expressed as a percentage of untreated
control cells and represent mean±s.d. (n¼ 3). Downregulation of
LMP7 significantly reduces sensitivity of KCL22S to carfilzomib
(P¼ 0.01). (f ) Proliferation of control LAMA84S cells and LAMA84S
cells transfected with either scrambled siRNA or siRNA targeted
against LMP7 following 24 h exposure to increasing doses of
carfilzomib (1–1000 nM). Results are expressed as a percentage
of untreated control cells and represent mean±s.d. (n¼ 3). Down-
regulation of LMP7 significantly reduces sensitivity of LAMA84S to
carfilzomib (P¼ 0.04).
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promoting the degradation of ABI-2 through TRIM32 is yet to be
fully delineated. Collectively, these results demonstrate a novel
mechanism of action for PIs in CML.
The effect of carfilzomib on the proliferation of imatinib-
sensitive and -resistant cell populations was evaluated using either
continuous treatment, or 1-h pulse treatment, which is more
reflective of the in vivo pharmacokinetics of carfilzomib. Both
methods induced a time- and dose-dependent decrease in
proliferation, with equal or greater sensitivity to carfilzomib
exhibited by imatinib-resistant cell lines compared with their
imatinib-sensitive counterparts. This is in agreement with earlier
studies demonstrating that imatinib resistance does not affect
sensitivity to PIs.20,21 The IC50 values obtained for carfilzomib in
CML cell lines are comparable to those reported for MM cell
lines,22 suggesting that these doses may be clinically relevant.
Heaney et al.,20 previously demonstrated that primitive CML stem
cells are sensitive to the apoptotic effects of bortezomib. Here we
also demonstrate an antiproliferative and apoptotic effect of
carfilzomib on the imatinib-resistant stem cell population.
Furthermore, we found that the stem cells enriched from CML
samples displayed greater sensitivity to carfilzomib than those
enriched from nonmalignant samples.
Having established an effect for carfilzomib as a single agent in
cell line models of imatinib-sensitive and -resistant CML, we also
looked at the effect of carfilzomib in combination with the TKIs
imatinib and nilotinib. In imatinib-sensitive cell lines, all combina-
tions of carfilzomib with either TKI resulted in synergistic effects.
Notably, we also observed that pretreatment with carfilzomib
sensitizes imatinib-resistant cells to TKIs. The mechanism behind
this synergistic effect is unclear; however, we demonstrate that it
is independent of Bcr-Abl activity. Similar effects have been
documented in a number of other studies using inhibitors of
signaling pathways downstream of Bcr-Abl. For example, the
combination of imatinib with chemotherapeutic agents,36 a Hsp90
inhibitor,37 PDK-1 inhibitor38 and leptomycin B39 have all been
shown to produce synergistic activity in imatinib-resistant cell
lines. The synergism between carfilzomib and TKIs was not
replicated in the CML-quiescent stem cell population, nonetheless
carfilzomib has a significant effect as a single agent in these cells.
Total levels of proteasome activity were found to be
significantly higher in primary CML cells compared with normal,
supporting previous observations by our group and others that
demonstrate an increase in proteasome activity in BCR-ABLþ
cells.21,32,40 Primary cells and cell lines exhibited both constitutive
proteasome and immunoproteasome subunits. Primary cells were
found to express a higher percentage of the LMP7 subunit than
CML cell lines. This pattern of higher immunoproteasome activity
in primary cells has also been observed in MM.26 Carfilzomib has
been reported to selectively inhibit the CT-L subunits (b5 and
LMP7) of the proteasome in MM and lymphoma cells.26,27 In
keeping with this, we show that carfilzomib inhibits CT-L subunits
with at least threefold selectivity compared with T-L and C-L
subunits.
Finally, we investigated whether the presence of immuno-
proteasome subunits in CML cells influences the sensitivity of the
cells to carfilzomib. Our group, along with others, have reported
that sensitivity of tumor cells to PIs is associated with proteasome
activity levels and subunit composition.28–30 In addition, Parlati
et al.,26 demonstrated that inhibition of either the b5 or LMP7
subunit alone was insufficient to produce an antitumor response
in hematopoietic cells. In this study, we found that the CML cell
line K562 exhibited little to no immunoproteasome activity and,
although carfilzomib was a potent inhibitor of the b5 subunit in
these cells, the IC50 for carfilzomib in K562 cells was 4fivefold
higher than that for the immunoproteasome-expressing cell lines.
Induction of immunoproteasome expression in K562 cells by IFN-g
resulted in an increase in sensitivity to carfilzomib, and this effect
was also replicated in the lung carcinoma cell line A549.
Conversely, knockdown of LMP7 expression reduced sensitivity
to carfilzomib in KCL22S and LAMA84S cells. These results suggest
that both CT-L subunits are required for optimal effect and that
proteasome composition may predict the response to carfilzomib.
In summary, this work shows that carfilzomib effectively
reduces proliferation and induces apoptosis in CML cell lines
and primary cells, regardless of their sensitivity to imatinib. We
have shown for the first time that proteasome inhibition in CML
cells is associated with a decrease in ERK signaling and increased
expression of the tumor suppressor ABI-2. Combination of
carfilzomib with TKIs has been demonstrated to generate
synergistic effects, even in imatinib-resistant cells, and the
presence of immunoproteasome subunits influences sensitivity
to carfilzomib. Taken together, these findings suggest that
carfilzomib could be a useful therapeutic agent in CML, and its
role in resensitizing imatinib-resistant cells to TKIs warrants further
investigation.
MATERIALS AND METHODS
Compounds
Imatinib and nilotinib were provided by Novartis Pharmaceuticals (Surrey,
UK) and reconstituted in sterile water or DMSO, respectively. Carfilzomib
was provided by Onyx Pharmaceuticals, Inc (South San Francisco, CA, USA)
and was reconstituted in DMSO.
Cells and culture conditions
A number of cell lines were used to reflect a spectrum of imatinib-sensitive
and -resistant disease. Ba/F3 cells transfected with p210 and mutated (T315I,
M351T, H396P) BCR-ABL were kindly provided by Dr. Brian Druker, (Oregon
Health and Science University, Portland, OR, USA). K562 cells were purchased
from the European Collection of Cell Cultures (Salisbury, UK). LAMA84
imatinib-sensitive and -resistant clones (LAMA84S and LAMA84R) and KCL22
imatinib-sensitive and -resistant clones (KCL22S and KCL22R) were provided
by Professor Junia Melo. LAMA84R cells have increased copy numbers of
BCR-ABL and express the multidrug resistance p-glycoprotein4 and the
mechanism of resistance in KCL22R cells is independent of BCR-ABL.41 Cells
were cultured in a humidified incubator at 37 1C and 5% CO2 in RPMI-1640
supplemented with 100U/ml penicillin, 100mg/ml streptomycin and 10%
fetal calf serum (Gibco BRL, Paisley, UK). LAMA84R and KCL22R cell lines
were cultured continuously in the presence of 1mM imatinib. A549 lung
carcinoma cells (European Collection of Cell Cultures) were cultured in
DMEM supplemented with 100U/ml penicillin, 100mg/ml streptomycin and
10% fetal calf serum. Authentication was conducted by LGC Standards Cell
Line Authentication Service.
Primary CML samples and normal controls
Leukapheresis products were obtained from CML patients at the time of
diagnosis and bone marrow from healthy donors was collected as a normal
control. All samples were obtained with ethical approval from the Research
Ethics Committee, Northern Ireland, and the National Health Service
Greater Glasgow Institutional Review Board and those involved gave their
informed consent in accordance with the Declaration of Helsinki. CD34þ
cells were enriched from the samples using an AutoMACS system
according to the manufacturer’s instructions (Miltenyi Biotech, Surrey,
UK). CD34þ cells were stained with CD34-APC and CD38 FITC (BD
Biosciences, Oxford, UK) and sorted using a FACSAria (BD Biosciences) to
obtain an enriched CD34þ38 population. CD34þ and CD34þ38 cells
were cultured in IMDM medium (Gibco BRL) supplemented with serum
substitute (bovine serum albumin, insulin, transferrin; StemCell Technol-
ogies, Grenoble, France), 2mM L-glutamine, 100U/ml penicillin, 100mg/ml
streptomycin, 0.1mM 2-mercaptoethanol and 0.8mg/ml low-density
lipoprotein (all from Sigma-Aldrich, Dorset, UK) and a growth factor
cocktail of 20 ng/ml recombinant human (rh) IL-3, 20 ng/ml rhIL-6, 100 ng/
ml rh Flt-3 ligand and 100 ng/ml rh stem cell factor (all from StemCell
Technologies).
Long-term culture initiating cell assay
CD34þ cells were overlaid on a pre-established irradiated (80Gy) stromal
layer of M2–10B4 cells (ATCC, Middlesex, UK) in Myelocult myeloid long-
term culture medium (StemCell Technologies). Cultures were maintained
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for 5 weeks with weekly half-medium changes. Cells were then harvested,
counted and transferred to Methocult media (StemCell Technologies).
After 2 weeks, colonies were counted using a light microscope.
Cell viability
CellTiter-Glo luminescent assay (Promega, Southampton, UK) was used to
analyze cell viability by measuring ATP levels according to the
manufacturer’s instructions. Luminescence was measured using a Tecan
Genios microplate reader (Tecan Genios, Reading, UK).
Cell proliferation
CyQUANT proliferation assay (Life Technologies, Paisley, UK) was used to
analyze cell proliferation by measuring cellular DNA content using a
fluorescent dye, according to the manufacturer’s instructions. Fluorescence
was measured using a Cytofluor Series 400 multiwell plate reader at an
excitation wavelength of 480 nM and emission wavelength of 520 nM.
Cell cycle analysis
Cells were harvested, washed in phosphate-buffered saline and fixed in
70% ethanol. Fixed cells were stained with 50mg/ml propidium iodide
(Sigma) for 30min. DNA content was subsequently measured using an LSR
II flow cytometer.
Caspase-3 activity
The Caspase-Glo 3 Assay (Promega) was used to determine caspase-3
activity by measuring cleavage of DEVD, according to the manufacturer’s
instructions. Luminescence was measured using a Tecan Genios microplate
reader.
Western blotting
Cells were harvested and lysed in radioimmunoprecipitation assay buffer
containing protease and phosphatase inhibitors. Immunoprecipitation
experiments were carried out using a crosslink immunoprecipitation kit
(Pierce, Thermo Scientific, Loughborough, UK), according to the manufac-
turer’s instructions. Equal amounts of protein were denatured in LDS sample
buffer (Invitrogen Ltd, Paisley, UK) at 95 1C for 5min, resolved by SDS–PAGE
on 10% Bis-Tris gels (Invitrogen Ltd) and subsequently transferred to a
polyvinylidene fluoride membrane. Immunoblotting was carried out using
antibodies against ubiquitin, phosphorylated (p)-ERK, ERK, p-PI3K, PI3K,
p-STAT5, STAT5, p-CRKL, cleaved caspase-3, cleaved caspase-8, cleaved
caspase-9 (all from Cell Signaling Technology, Hertfordshire, UK), TRIM32 and
GAPDH (both from Abcam, Cambridge, UK) and ABI 1/2 (kindly provided by
Dr. Karim Dib, Queen’s University Belfast) or ABI-2 (Abcam) and secondary
antibodies anti-mouse and anti-rabbit (DAKO, Stockport, UK). Blots were
scanned into the AutoChemi System (UVP, Cambridge, UK) and densitometry
analysis was performed using LabWorks 4.5 image acquisition and analysis
software. Values obtained were corrected to loading controls and are
expressed as a percentage of untreated controls. The average values for three
replicate experiments are shown for each cell line.
ProCISE assay
A proteasome active site ELISA by name of ProCISE (Proteasome
Constitutive/Immunoproteasome Subunit ELISA) was used to measure
each proteasome subunit activity of the constitutive and immuno-
proteasome in homogenates of cell samples. This assay was performed
as previously described in.26
Analysis of drug combinations
The median effect of Chou–Talalay was employed to analyze the effect of
carfilzomib in combination with imatinib or nilotinib using Calcusyn
software (Biosoft, Cambridge, UK).42 The values used for the analysis were
derived from cell viability as measured by CellTiter-Glo.
Inhibition of gene expression by siRNA
K562, KCL22S or LAMA84S cells were nucleofected following the
manufacturer’s instructions using the Cell Line Nucleofector Kit V, program
T-03 (Amaxa, Lonza, Castleford, UK) and either siRNA directed against BCR-
ABL (50-GCA GAG AGU UCA AAA GCC CUU-30), LMP7 (Silencer Select siRNA
ID s11360, Life Technologies) or a scrambled siRNA sequence (50-UUG UAC
GGC AUC AGC GUU ATT-30).
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